La Jolla Pharmaceutical Company


La Jolla Pharmaceutical Company (LJPC): Why Cowen Analyst Sees More Upside

La Jolla Pharmaceutical Company (NASDAQ:LJPC) investors are overwhelmingly excited today after the drug maker reported compelling results from a phase 3 trial of its hypotension …

Monday’s Market Insights: HTG Molecular Diagnostics Inc (HTGM), La Jolla Pharmaceutical Company (LJPC), Shutterstock Inc (SSTK)

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) shares skyrocketed today, up by 135% as of 02:35 p.m.

Company Update (NASDAQ:LJPC): La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501

La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, …

Company Update (NASDAQ:LJPC): La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results and Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, …

Chardan Raises Price Target For La Jolla Pharmaceutical Company Following Meeting with CEO

Chardan Capital analyst Gbola Amusa weighed in today with a favorable report on La Jolla Pharmaceutical Company (NASDAQ:LJPC), reiterating a Buy rating and raising the price target …

Stock Update (NASDAQ:LJPC): La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening …

Stock Update (NASDAQ:LJPC): La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb

La Jolla Pharmaceutical Company (NASDAQ:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, …

Oppenheimer Initiates Outperform on La Jolla Pharmaceutical Company; Sees 125% Upside for the Stock

In a research report published April 20, Oppenheimer analyst Ling Wang initiated coverage on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) with an Outperform …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts